non-small cell lung cancer
Conditions
Interventions
photon radiotherapy group:18F-MISO/PETCT scanning,photon radiotherapy
carbon-ion radiotherapy group:18F-MISO/PETCT scanning, carbon-ion radiotherapy
Sponsors
Shanghai Proton and Heavy Ion Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Sign informed consent; 2) Age =18 years old; 3) Have the ability to comply with the scheme; 4) cytological or histological identification of lung lesions is required; 5) Non-small cell lung cancer confirmed by cytology or histology; T=3cmN0-3M0 (UICC/AJCC 8th edition); 6) Patients who cannot (after thoracic surgery evaluation) for medical reasons, or patients who refuse surgery, willing to receive carbon ion or photon radiotherapy; 7) Patients who need synchronous chemotherapy in principle but cannot tolerate or refuse synchronous chemotherapy due to medical reasons; 8) KPS score is greater than or equal to 60, ECOG general status score is 0-1 (at least can walk around freely and take care of themselves, and can get up and do activities for at least half of the day); 9) The expected survival period is greater than or equal to 12 months; 10) Adequate organ function to meet the basic requirements for the treatment required.
Exclusion criteria
Exclusion criteria: ) The patient's disease has not been confirmed by pathology; 2) Complicated with other malignant tumors and has not been controlled; 3) The toxic and side effects of previous treatment have not recovered, such as systemic chemotherapy or targeted therapy and other anti-cancer treatment interval <1 month; 4) Patients for whom the radiotherapy plan fails to meet the minimum target dose coverage and dose volume limits, or fails to meet the dose limits of normal organs; 5) Have received thoracic radiotherapy or radioactive particle implantation in the past; (6) Pacemakers or other metal implants that may be affected by high-energy radiation interference with normal function or that may affect radiation target dose; 7) pregnancy (confirmed by serum or urine ß-HCG test) or lactation; 8) Being HIV positive, including having taken antiretroviral therapy; Chronic hepatitis B virus replication stage; Hepatitis C active phase; Active stage of syphilis; 9) HBV positive patients with hepatitis virus replication stage need to receive antiviral therapy, but cannot receive antiviral therapy because of the accompanying disease; 10) With severe comorbidities that may affect radiotherapy, including: a) acute infectious diseases; Or the acute active phase of chronic infection; b) Unstable angina pectoris, congestive heart failure, myocardial infarction requiring hospitalization in the past 6 months; c) hospitalization for exacerbations of COPD or other respiratory diseases; d) severely impaired immune function; e) Hypersensitivity to radiation, such as ataxia telangiectasia; f) being pregnant or lactating; g) Other diseases that may affect particle therapy; 11) having no or limited capacity for civil conduct; 12) Drug abuse or alcohol dependence, or a history of mental illness, who cannot understand the treatment or the purpose of this study or may hinder the completion of treatment; 13) Unwilling/unable to sign informed consent; 14) Situations in which other physicians consider it inappropriate to participate in clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| local control rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival rate;cause-specific survival rate;overall survival rate;disease-free survival rate; | — |
Countries
China
Contacts
Public ContactJingfang Mao, Jian Chen, Jiade Lu
Shanghai Proton and Heavy Ion Center
Outcome results
None listed